These findings collectively unveil a mechanism of resistance against anti-HER2 treatments and propose a potential strategy to counter this resistance by inhibiting FGFR4 in challenging cases of HER2-positive BC [66]. This evidence concerns the gene FGFR4 and breast cancer.